Therapeutics News and Research

RSS

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project “FLUCURE” supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germany, Bulgaria, Lithuania, and the Netherlands.

23 Feb 2011

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project "FLUCURE" supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses.

23 Feb 2011

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Tranzyme Pharma and Norgine B.V., have initiated dosing of ulimorelin in the first of two, Phase 3 pivotal studies - ULISES. Ulimorelin is Tranzyme's intravenous promotility agent in development for the management of postoperative ileus in hospital and acute care settings.

23 Feb 2011

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Omeros Corporation today announced that its exclusive license to phosphodiesterase 7 inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use.

23 Feb 2011

USPTO issues patent to Silence Therapeutics' siRNA technology

Silence Therapeutics plc announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office.

23 Feb 2011

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program, currently under evaluation for the treatment of cancer.

22 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Scientists identify new cellular mechanism underlying hydronephrosis

One of the most common congenital defects in humans - it is detected in approximately 0.5% of fetuses analyzed by routine antenatal sonography - is a kidney abnormality known as hydronephrosis. Hydronephrosis arises because the flow of urine from the kidney to the bladder is impeded.

21 Feb 2011

Researchers receive $2 million NIH grant to identify biomarkers in children with hemangiomas

A nearly $2 million grant from the National Institutes of Health will help investigators at Nationwide Children's Hospital search for biomarkers that may be linked to the development and outcome of hemangiomas, the most common soft tissue tumor in children.

21 Feb 2011

How Huntington's disease proteins move from cell to cell

One bad apple is all it takes to spoil the barrel. And one misfolded protein may be all that's necessary to corrupt other proteins, forming large aggregations linked to several incurable neurodegenerative diseases such as Huntington's, Parkinson's and Alzheimer's.

19 Feb 2011

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

Scientists at the Children's Center for Cancer and Blood Diseases and The Saban Research Institute of Children's Hospital Los Angeles today announced a breakthrough discovery in understanding how the body fights leukemia.

18 Feb 2011

Chelsea prices underwritten public offering of 8.75 million shares of common stock

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of 8.75 million shares of its common stock at a price of $4.00 per share which will result in gross proceeds of $35 million.

18 Feb 2011

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

BioMimetic Therapeutics, today announced highlights from its analyst and investor meeting which was held on Thursday, February 17 in San Diego, CA in conjunction with the American Academy of Orthopedic Surgery Annual Meeting.

18 Feb 2011

TI Pharma launches new research project on stem cell transplant

Top Institute Pharma is today launching a new research project that should make stem cell transplants more successful. A stem cell transplant is usually performed on adults with acute leukemia.

18 Feb 2011

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, securities in a registered offering to a single life sciences institutional investor. The Company may use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.

18 Feb 2011

Intrinsic initiates enrollment in Barricaid device clinical trial

Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.

18 Feb 2011

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

Therapeutics News and Research

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

USPTO issues patent to Silence Therapeutics' siRNA technology

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Forest Labs enters definitive merger agreement to acquire Clinical Data

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Scientists identify new cellular mechanism underlying hydronephrosis

Researchers receive $2 million NIH grant to identify biomarkers in children with hemangiomas

How Huntington's disease proteins move from cell to cell

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

Chelsea prices underwritten public offering of 8.75 million shares of common stock

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

TI Pharma launches new research project on stem cell transplant

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Intrinsic initiates enrollment in Barricaid device clinical trial

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News